BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 19028034)

  • 1. Recent advances in neurobiology of Tuberous Sclerosis Complex.
    Napolioni V; Moavero R; Curatolo P
    Brain Dev; 2009 Feb; 31(2):104-13. PubMed ID: 19028034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diverse clinical manifestations of tuberous sclerosis complex: a review.
    Rosser T; Panigrahy A; McClintock W
    Semin Pediatr Neurol; 2006 Mar; 13(1):27-36. PubMed ID: 16818173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
    Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL
    Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.
    Lee L; Sudentas P; Dabora SL
    Genes Chromosomes Cancer; 2006 Oct; 45(10):933-44. PubMed ID: 16845661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
    Astrinidis A; Henske EP
    Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberous sclerosis complex and epilepsy: recent developments and future challenges.
    Holmes GL; Stafstrom CE;
    Epilepsia; 2007 Apr; 48(4):617-30. PubMed ID: 17386056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
    Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
    Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of mTOR in tuberous sclerosis.
    Sampson JR
    Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tuberous sclerosis complex proteins--a GRIPP on cognition and neurodevelopment.
    de Vries PJ; Howe CJ
    Trends Mol Med; 2007 Aug; 13(8):319-26. PubMed ID: 17632034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neurobiology of tuberous sclerosis complex.
    Ess KC
    Semin Pediatr Neurol; 2006 Mar; 13(1):37-42. PubMed ID: 16818174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex.
    Cambiaghi M; Cursi M; Magri L; Castoldi V; Comi G; Minicucci F; Galli R; Leocani L
    Neuropharmacology; 2013 Apr; 67():1-7. PubMed ID: 23159330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment.
    Jozwiak J; Jozwiak S; Oldak M
    Med Res Rev; 2006 Mar; 26(2):160-80. PubMed ID: 16329102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of epilepsy in tuberous sclerosis complex.
    Curatolo P; D'Argenzio L; Cerminara C; Bombardieri R
    Expert Rev Neurother; 2008 Mar; 8(3):457-67. PubMed ID: 18345974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis.
    Waltereit R; Welzl H; Dichgans J; Lipp HP; Schmidt WJ; Weller M
    J Neurochem; 2006 Jan; 96(2):407-13. PubMed ID: 16300636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving neurobiology of tuberous sclerosis complex.
    Crino PB
    Acta Neuropathol; 2013 Mar; 125(3):317-32. PubMed ID: 23386324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
    Kenerson H; Dundon TA; Yeung RS
    Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberous sclerosis complex: disease modifiers and treatments.
    Au KS; Ward CH; Northrup H
    Curr Opin Pediatr; 2008 Dec; 20(6):628-33. PubMed ID: 19005330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2.
    Tavazoie SF; Alvarez VA; Ridenour DA; Kwiatkowski DJ; Sabatini BL
    Nat Neurosci; 2005 Dec; 8(12):1727-34. PubMed ID: 16286931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberous sclerosis complex: advances in diagnosis, genetics, and management.
    Schwartz RA; Fernández G; Kotulska K; Jóźwiak S
    J Am Acad Dermatol; 2007 Aug; 57(2):189-202. PubMed ID: 17637444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.